| First Author | Sun CP | Year | 2021 |
| Journal | PLoS Pathog | Volume | 17 |
| Issue | 8 | Pages | e1009758 |
| PubMed ID | 34379705 | Mgi Jnum | J:322631 |
| Mgi Id | MGI:6793118 | Doi | 10.1371/journal.ppat.1009758 |
| Citation | Sun CP, et al. (2021) Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathog 17(8):e1009758 |
| abstractText | Since the pandemic of COVID-19 has intensely struck human society, small animal model for this infectious disease is in urgent need for basic and pharmaceutical research. Although several COVID-19 animal models have been identified, many of them show either minimal or inadequate pathophysiology after SARS-CoV-2 challenge. Here, we describe a new and versatile strategy to rapidly establish a mouse model for emerging infectious diseases in one month by multi-route, multi-serotype transduction with recombinant adeno-associated virus (AAV) vectors expressing viral receptor. In this study, the proposed approach enables profound and enduring systemic expression of SARS-CoV-2-receptor hACE2 in wild-type mice and renders them vulnerable to SARS-CoV-2 infection. Upon virus challenge, generated AAV/hACE2 mice showed pathophysiology closely mimicking the patients with severe COVID-19. The efficacy of a novel therapeutic antibody cocktail RBD-chAbs for COVID-19 was tested and confirmed by using this AAV/hACE2 mouse model, further demonstrating its successful application in drug development. |
